NCT06400589View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

PHASE3SuspendedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Dry Eye
Interventions
DRUG

tanfanercept

TNF inhibitor

DRUG

Vehicle

Same composition as tanfanercept but without the active ingredient

Trial Locations (1)

33484

HanAll Site #1, Delray Beach

Sponsors
All Listed Sponsors
lead

HanAll BioPharma Co., Ltd.

INDUSTRY

NCT06400589 - A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease | Biotech Hunter | Biotech Hunter